| Name | Title | Contact Details |
|---|
United Claim Solutions was started by Joshua Carder in 2004. Joshua had been in the cost containment industry for a number of years, and through that experience realized there were efficiencies and solutions that could be introduced to lower medical and administrative costs for self-insured employers, labor organizations, payers and insurers. The mission of United Claim Solutions is to be a leader and innovator of products and services for healthcare payers. We will provide superior Service, Savings and Solutions to our customers while never compromising the quality of care delivered to covered individuals.
Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.
SonoNet is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Independent Beachbody Coach is a Wilsonville, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The RNS® System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world`s first and only medical device that can monitor and respond to brain activity. NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company`s initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.